

Coordination compounds of *N,N'*-olefin functionalized imidazolin-2-ylidenes

Ekkehardt F. Hahn*, Beate Heidrich, Alexander Hepp, Tania Pape

Institut für Anorganische und Analytische Chemie, Westfälische Wilhelms Universität Münster, Corrensstraße 36, 48149 Münster, Germany

Received 27 March 2007; received in revised form 13 April 2007; accepted 13 April 2007

Available online 24 April 2007

Abstract

N-Heterocyclic carbene ligands (NHC) were metalated with Pd(OAc)₂ or [Ni(CH₃CN)₆](BF₄)₂ by *in situ* deprotonation of imidazolium salts to give the *N*-olefin functionalized biscarbene complexes [MX₂(NHC)₂] **3–7** (**3**: M = Pd, X = Br, NHC = 1,3-di(3-butenyl)imidazolin-2-ylidene; **4**: M = Pd, X = Br, NHC = 1,3-di(4-pentenyl)imidazolin-2-ylidene; **5**: M = Pd, X = I, NHC = 1,3-diallylimidazolin-2-ylidene; **6**: M = Ni, X = I, NHC = 1,3-diallylimidazolin-2-ylidene; **7**: M = Ni, X = I, NHC = 1-methyl-3-allylimidazolin-2-ylidene). Molecular structure determinations for **4–7** revealed that square-planar complexes with *cis* (**5**) or *trans* (**4**, **6**, **7**) coordination geometry at the metal center had been obtained. Reaction of nickelocene with imidazolium bromides afforded the η⁵-cyclopentadienyl (η⁵-Cp) monocarbene nickel complexes [NiBr(η⁵-Cp)(NHC)] **8** and **9** (**8**: NHC = 1-methyl-3-allylimidazolin-2-ylidene; **9**: NHC = 1,3-diallylimidazolin-2-ylidene). The bromine abstraction in complexes **8** and **9** with silver tetrafluoroborate gave complexes [NiBr(η⁵-Cp)(η³-NHC)] **10** and **11**. The X-ray structure analysis of **10** and **11** showed a trigonal-pyramidal coordination geometry at the nickel(II) center and coordination of one *N*-allyl substituent.

© 2007 Elsevier B.V. All rights reserved.

Keywords: Carbene; *N*-Olefin substituent; Palladium(II); Nickel(II); Structure determination

1. Introduction

N-Heterocyclic carbenes (NHCs) have attracted much interest due to the diversity in the *N*-substitution pattern and their application in homogeneous catalysis as ligands for catalytically active metal centers [1]. Mainly regarded as strong σ-donors, NHCs are often compared to tertiary phosphines due to their similar electronic properties and their ability to stabilize various oxidation states and coordinatively unsaturated intermediates appearing in catalytic reactions. However, NHCs exhibit superior qualities regarding ligand dissociation which is more unlikely compared to tertiary phosphines which leads to a higher complex stability [2]. Particularly palladium and nickel complexes have frequently been reported to show high cat-

alytic activity in Heck or Suzuki coupling or polymerization reactions [3]. The ongoing interest in palladium catalyzed Heck type coupling reactions is illustrated by the large number of reviews dealing with this topic [4]. Compared to palladium, much fewer nickel NHC complexes are known.

Hemilabile coordination is an established concept in catalytic research. This concept implies the presence of both strong and weak donor groups in one ligand. The strong donor remains coordinated to the metal center, while the weak donor is able to coordinate reversibly and hence to free coordination sites during a catalytic cycle [5]. This concept has been transferred successfully to NHC ligands. Nitrogen, oxygen and lately sulfur donor groups fixed at NHCs have been reported to function as hemilabile ligands. Complexes with this type of ligands were tested in different catalytic reactions [6].

The success of this concept prompted us to synthesize analogous hemilabile systems bearing donor groups other


* Corresponding author. Tel.: +49 251 833 3111; fax: +49 251 833 3108.
E-mail address: fehahn@uni-muenster.de (E.F. Hahn).

than N, O, or S. Investigation of complexes with *N*-allyl substituted azolin-ylidenes showed hemilabile behavior of these ligands due to allyl double bond coordination to different transition metal centers [7–9]. Nickel complexes with tertiary phosphine and olefin substituted indenyl or tetramethylcyclopentadienyl ligands are also capable of coordination of the olefinic double bond to the nickel center. Studies with these complexes showed an enhanced stability and catalytic activity [10]. We report here on the synthesis and characterization of palladium and nickel complexes with *N*-olefin substituted imidazolin-2-ylidenes and on methods to achieve simultaneous coordination of both the carbene and the olefinic double bond to the nickel(II) center.

2. Results and discussion

The symmetrically substituted imidazolium salts 1,3-di(3-butenyl)- (1) and 1,3-di(4-pentenyl)imidazolium bromide (2) were synthesized by reaction of imidazole and NaHCO₃ as a base with 4-bromobutene or 5-bromopentene, respectively, in acetonitrile [8]. The reaction afforded 1 as a colorless oil of high viscosity, which crystallizes upon standing for several weeks. The imidazolium salt 2 was obtained as a brown oil. Both salts are very hygroscopic. The imidazolium salts were identified by NMR spectroscopy. The ¹H NMR spectra exhibit the resonances for the NCHN protons with a typical downfield shift of $\delta = 10.57$ (1) and 10.71 ppm (2). Due to ²J_{HH} and ³J_{HH} coupling of the terminal olefinic protons the resonances for the CH=CH₂ protons appear as doublet of doublets at $\delta_{cis} = 5.09$ (1) and 5.02 ppm (2) and $\delta_{trans} = 5.06$ (1) and 5.05 ppm (2), respectively. They exhibit the typical coupling constants of ³J_{HH,cis} = 10.4 Hz and ³J_{HH,trans} = 17.2 Hz. These coupling constants are also found for the characteristic multiplet for the CH=CH₂ proton signal at $\delta \approx 5.8$ ppm (for both 1 and 2) with an additional ³J_{HH} coupling constant of 6.8 Hz attributable to coupling to the neighboring methylene group. The coupling scheme described above for the ¹H NMR spectra of 1 and 2 is typical and indicative for all compounds described below bearing olefin substituents without C=C double bond coordination to a metal center.

N-Allylbenzimidazolium salts are known to undergo rearrangement reactions upon C² deprotonation instead of formation of the free carbene ligand [9a,11]. However, complexes with *N*-allylimidazolin-2-ylidene and *N*-allylbenzimidazolin-2-ylidene ligands can be obtained by reaction of theazolium salt with metal salts which contain basic anions [8,12]. For example, palladium NHC complexes were prepared by *in situ* deprotonation of 1,3-diallylimidazolium bromide and the imidazolium bromides 1 and 2 with Pd(OAc)₂ in THF according to Scheme 1. Complexes 3 and 4 were obtained at moderate temperatures. Based on investigations on thermally induced *cis-trans* isomerization of palladium NHC complexes [13], the *cis-*



Scheme 1. Preparation of *cis-* and *trans*-palladium(II) complexes 3–5.

complex 5 was synthesized by reaction of 1,3-diallylimidazolium bromide with Pd(OAc)₂, an excess of NaI and heating under reflux in THF (Scheme 1). The complex was obtained as pale yellow crystals by recrystallization from dichloromethane/diethyl ether.

¹H NMR spectra of complexes 3 and 4 show the characteristic multiplet for the CH=CH₂ proton around $\delta \approx 5.9$ ppm. The terminal protons of the C=C double bond of the olefin arms give rise to a resonance for the CH=CHH_{trans} protons around $\delta \approx 5.1$ ppm with a characteristic coupling constant ³J_{HH} of about 17 Hz. The CH=CHH_{cis} signal is found around $\delta = 5.0$ ppm with the typical ³J_{HH} coupling constant of about 10 Hz. Compared to the salts 1 and 2 the resonances for the olefinic protons in complexes 3 and 4 show no significant high field shift, hence coordination of the C=C double bond to the metal center can be excluded [7–9]. The resonances for the carbene carbon atoms were detected at $\delta = 171.8$ (1) and $\delta = 168.5$ ppm (2), respectively.

The molecular structure of complex 4 was determined by X-ray diffraction and is shown in Fig. 1. Consistent with the NMR data, it shows the *N*-pentenyl substituents to be uncoordinated. The structural analysis confirms the square-planar coordination geometry at the palladium center with a *trans*-configuration of identical ligands. The imidazolin-2-ylidene planes are oriented almost perpendicular to the PdC₂Br₂ plane with interplane angles of 75.7° and 81.3°, respectively, which is a common observation for *trans*-[MX₂(NHC)₂] complexes [3c,14]. The Pd–C_{carbene} bond lengths of 2.018(3) and 2.024(3) Å are comparable to reported *trans*-[PdBr₂(NHC)₂] palladium complexes [12a].

The protons of the terminal CH=CH₂ groups in complex 5 appear in the ¹H NMR spectrum also as doublet of doublets with the typical coupling constants ²J_{HH} = 10.2 Hz (*cis*) and ³J_{HH} = 17.1 Hz (*trans*). The resonance of the carbene carbon atom was detected at $\delta = 167.5$ which is a value in the typical range for complexes of type *cis*-[PdI₂(NHC)₂] (NHC = imidazolin-2-ylidene) [15].




Fig. 1. Molecular structure of complex **4**. Selected bond lengths (Å) and angles (°): Pd–Br1 2.4378(6), Pd–Br2 2.4417(6), Pd–C1 2.018(3), Pd–C20 2.024(3), N1–C1 1.354(4), N2–C1 1.345(5), N3–C20 1.352(4), N4–C20 1.353(4); Br1–Pd–Br2 178.25(2), Br1–Pd–C1 90.41(10), Br1–Pd–C20 90.05(10), Br2–Pd–C1 89.30(10), Br2–Pd–C20 90.27(10), C1–Pd–C20 179.03(15), N1–C1–N2 104.6(3), N3–C20–N4 104.6(3).

The molecular structure of **5** is depicted in Fig. 2. Identical ligands adopt a *cis*-arrangement at the palladium atom coordinated in a square-planar fashion. The Pd–I bond lengths of 2.6423(5) and 2.6411(5) Å lie within the expected range for *cis*-[PdI₂(NHC)₂] complexes. Compared to *trans*-[PdI₂(NHC)₂] [16] complexes the Pd–I bonds are elongated in **5** which we attribute to the stronger *trans*-influence of the carbene ligand. Consequently, the Pd–C_{carbene} bond lengths in complex **5** (1.993(4) and 2.004(4) Å) are slightly shorter than in complexes of type *trans*-[PdI₂(NHC)₂] [16]. The C–Pd–C angle is slightly smaller (91.15(14)°) than the I1–Pd–I2 angle (93.18(2)°). The imidazole planes are oriented almost perpendicular to each





Fig. 2. Molecular structure of complex **5**. Selected bond lengths (Å) and angles (°): Pd–I1 2.6423(5), Pd–I2 2.6411(5), Pd–C1 1.993(4), Pd–C12 2.004(4), N2–C1 1.355(5), N5–C1 1.351(4), N13–C12 1.353(5), N16–C12 1.347(5); I1–Pd–I2 93.18(2), I1–Pd–C1 88.14(9), I1–Pd–C12 175.64(11), I2–Pd–C1 172.76(10), I2–Pd–C12 88.06(10), C1–Pd–C12 91.15(14), N2–C1–N5 104.8(3), N13–C12–N16 104.9(3).

other, with a dihedral angle between the planes of 88.9°. Both planes of the carbene rings are rotated relative to the PdI₂ plane with dihedral angles of 80.1–84.8°. Compared to the analogous 1,3-dimethylimidazolin-2-ylidene palladium complex these angles are significantly larger due to enhanced steric demand of the *N*-allyl substituents in **5** [15].

The nickel(II) complexes **6** and **7** (Scheme 2) were prepared by reaction of 1,3-diallylimidazolium bromide or 1-methyl-3-allylimidazolium bromide with potassium-*tert*-butoxide as a base, sodium iodide and hexakisacetonitrile-nickel(II) tetrafluoroborate in dichloromethane. The air-stable complexes were obtained in moderate yields of about 40%.

The ¹H NMR spectrum of complex **6** shows the CH=CH₂ signal at δ = 6.29 ppm with the typical ³J_{HH} coupling constants (to NCH₂ 6.0 Hz, to CH=CH_{cis} 10.2 Hz and CH=CH_{trans} 17.0 Hz). The resonances of the terminal allylic methylene moiety are detected at δ_{trans} = 5.46 ppm and δ_{cis} = 5.37 ppm (³J_{HH,cis} = 10.1 Hz). The carbene carbon atom resonance is found at δ = 173.7 ppm.

The ¹H and ¹³C NMR spectra of complex **7** with the unsymmetrically substituted imidazolin-2-ylidene ligand indicate the presence of two conformers (*syn* and *anti*) in solution, a behavior which has been observed for similar complexes of type *trans*-[NiI₂(NHC)₂] [3c]. At ambient temperature the two sets of signals in a 1:1 ratio were detected for some resonances. The resonance for the C² carbon atom was observed for both conformers at δ = 173.9 ppm in the ¹³C NMR spectrum. The resonances for the N–CH=CH–N carbon atoms, however, appear as split signals (δ = 121.1, 121.0 ppm and δ = 123.4, 123.3 ppm). In addition, unresolved multiplets were observed for the CH=CH₂ protons in the ¹H NMR




Scheme 2. Preparation of complexes **6** and **7**.

spectrum. No indications for a significant barrier for the rotation around the M–C_{carbene} bond was found, while for related examples the steric bulk of the *N*-substituents has been held responsible for a hindered rotation [6b,17]. Reasonable assignments of the resonances in the NMR spectra of **6** and **7** were only possible by 2D NMR techniques owing to overlapping signals and line broadening caused by paramagnetic impurities.

Crystals suitable for X-ray diffraction studies were grown by slow diffusion of diethyl ether into saturated dichloromethane solutions of **6** or **7**. Identical ligands are arranged in a *trans*-fashion in both complexes. The carbene ring planes are oriented almost perpendicular to the NiC₂I₂ coordination plane in both complexes with dihedral angles between these planes of 84.1° in both cases. The Ni–I (2.5086(4) Å (**6**) and 2.5040(5) Å (**7**)) and Ni–C bond lengths (1.908(4) Å (**6**) and 1.901(6) Å (**7**)) fall in the typical range found for similar imidazolin-2-ylidene complexes [3c,14,18] (Fig. 3).

Following a modified version of the described procedure for the reaction of nickelocene with imidazolium salts [19] the reaction of 1-methyl-3-allylimidazolium bromide and 1,3-diallylimidazolium bromide with nickelocene afforded the monocarbene nickel complexes **8** and **9** (Scheme 3). The resonances for the carbene carbon atoms are quite similar in **8** ($\delta = 162.4$ ppm) and **9** ($\delta = 160.3$ ppm). Chemical shifts and coupling patterns for the allyl groups in both **8** and **9** indicate that the double bonds are not coordinated to the nickel center. Two resonances were observed for the N–CH₂–CH=CH₂ protons indicating that these are diastereotopic in both **8** and **9**. This indicates a hindered rotation around the Ni–C_{carbene} bond at ambient temperature. Removal of the bromine ligand in complexes **8** and **9** by reaction with AgBF₄ in dichloromethane afforded the cationic complexes **10** and **11** each containing one coordinated allylic double bond (Scheme 3).

Coordination of the allylic double bond to the nickel center results in a significant high field shift of the



Scheme 3. Preparation of complexes **8–11**.

resonances for the CH=CH₂ protons of the coordinated double bond in the ¹H NMR spectra of complexes **10** and **11**, an observation previously described for *N*-allyl double bond coordination to metal centers [7–9,20]. The terminal methylene groups of the coordinated double bonds give rise to two signals around $\delta \approx 4.1$ ppm (*cis*) and $\delta \approx 3.2$ ppm (*trans*). A significant change in the ³J_{HH,*cis*} (8 Hz) and ³J_{HH,*trans*} (14 Hz) coupling constants is observed upon coordination relative to the uncoordinated allyl group. The ¹H and ¹³C NMR spectra of complex **11**




Fig. 3. Molecular structures of complexes **6** and **7**. The asymmetric unit contains one half of the complex, related to the other half by an inversion center for each complex. Selected bond lengths (Å) and angles (°) for **6** [**7**]: Ni–I1 2.5086(4) [2.5040(5)], Ni–C1 1.908(4) [1.901(6)], C1–N1 1.352(5) [1.355(8)], C1–N2 1.352(5) [1.350(8)], I1–Ni–C1 90.06(11) [88.5(2)], I1–Ni–C1* 89.94(11) [91.5(2)], N1–C1–N2 104.6(3) [104.9(5)].




Fig. 4. Molecular structures of complexes **10** and **11**. The tetrafluoroborate anion is not shown. Selected bond lengths (Å) for **10** [**11**]: Ni–C1 1.882(4) [1.872(2)], Ni–C5 2.037(4) [2.034(2)], Ni–C6 2.032(4) [2.036(2)], Ni–Cp_{centroid} 1.720 [1.716], C1–N1 1.347(5) [1.348(3)], C1–N2 1.341(5) [1.348(3)], for **11** C13–C14 1.309(3); N1–C1–N2 105.3(3) [105.0(2)].

exhibit resonances of two different allyl groups. One set of signals shows similar chemical shifts and H,H coupling constants as were observed for the uncoordinated allyl groups in complexes **8** and **9**. This allows the assignment of the resonances recorded for complex **11** which contains a coordinated and an uncoordinated allyl group.

The resonances for the cyclopentadienyl protons experience a downfield shift from $\delta \approx 5.3$ ppm for **8** and **9** to $\delta \approx 5.8$ ppm upon coordination of the allylic double bond in **10** and **11**. We attribute this to the coordination of the C=C double bond as a σ -donor/ π -acceptor, which weakens the Ni–Cp π -interactions.

The molecular structures of complexes **10** and **11** were determined by X-ray diffraction (Fig. 4). Consistent with the NMR data the structure analyses confirm the presence of one η^2 -coordinated C=C double bond in each complex. In complex **11** the second allyl donor of the carbene ligand is dangling. The overall geometry around the metal center can be described as trigonal-pyramidal for both complexes by taking the Cp_{centroid}, the center of the coordinated C=C double bond and the carbene carbon atom as vertices of the trigonal plane. The nickel atom is regarded as apex of the pyramid with a distance of 0.3 Å above the center of the triangle. Bond lengths of the nickel center to the Cp_{centroid} of about 1.72 Å and Ni–C_{carbene} bond lengths of 1.882(4) Å (**10**) and 1.872(2) Å (**11**) are comparable to those found for similar [NiCpCl(NHC)] complexes [21]. The distances between the nickel center and the carbon atoms of the allylic double bond measure around 2.03 Å and thus are similar to those described in literature for double bond coordination of olefin substituted cyclopentadienyl ligands to nickel(II) [10a].

3. Experimental

3.1. General comments

All manipulations were performed in an atmosphere of dry argon by using standard Schlenk techniques, unless stated otherwise. Solvents were dried by standard methods

and distilled under argon prior to use. 1,3-Diallylimidazolium bromide [12a] and 1-methyl-3-allylimidazolium bromide [8b] were prepared by published methods. The spectra were referenced internally using the residual signal of the solvent. Assignments for complexes **6–11** were done by ^{13}C and ^1H 2D NMR spectroscopy.

3.2. Preparation of imidazolium salts

3.2.1. 1,3-Di(3-butenyl)imidazolium bromide (**1**)

A suspension of 544 mg (8.0 mmol) imidazole and 680 mg (8.1 mmol) of sodium hydrogencarbonate in acetonitrile (15 mL) was treated with 1.9 mL (18.7 mmol) of 4-bromobutene. The reaction mixture was heated under reflux for 12 h and was then filtered. Removal of all volatiles gave **1** as a colorless oil. Yield: 1.66 g (81%).

Elemental Anal. Calc. for $\text{C}_{11}\text{H}_{17}\text{N}_2\text{Br}$: C, 51.37; H, 6.66; N, 10.89. Found: C, 50.70; H, 6.94; N, 10.97%. ^1H NMR (400.1 MHz, CDCl_3): δ = 10.57 (s, 1H, NCHN), 7.39 (d, $^2J_{\text{HH}} = 2.0$ Hz, 2H, NCHCHN), 5.78 (ddt, $^3J_{\text{HH,trans}} = 17.2$ Hz, $^3J_{\text{HH,cis}} = 10.4$ Hz, $^3J_{\text{HH}} = 6.8$ Hz, 2H, $\text{NCH}_2\text{CH}_2\text{CH}=\text{CH}_2$), 5.09 (dd, $^2J_{\text{HH}} = 1.2$ Hz, $^3J_{\text{HH}} = 10.4$ Hz, 2H, $\text{NCH}_2\text{CH}_2\text{CH}=\text{CH}_{\text{cis}}$), 5.06 (dd, $^2J_{\text{HH}} = 1.2$ Hz, $^3J_{\text{HH}} = 17.2$ Hz, 2H, $\text{NCH}_2\text{CH}_2\text{CH}=\text{CH}_{\text{trans}}$), 4.45 (t, $^3J_{\text{HH}} = 6.8$ Hz, 4H, $\text{NCH}_2\text{CH}_2\text{CH}=\text{CH}_2$), 2.66 (dt, $2 \times ^3J_{\text{HH}} = 6.8$ Hz, 4H, $\text{NCH}_2\text{CH}_2\text{CH}=\text{CH}_2$). ^{13}C NMR (50.3 MHz, CDCl_3): δ = 135.8 (NCHN), 131.6 ($\text{NCH}_2\text{CH}_2\text{CH}=\text{CH}_2$), 121.7 (NCHCHN), 118.8 ($\text{NCH}_2\text{CH}_2\text{CH}=\text{CH}_2$), 48.2 ($\text{NCH}_2\text{CH}_2\text{CH}=\text{CH}_2$), 33.7 ($\text{NCH}_2\text{CH}_2\text{CH}=\text{CH}_2$).

3.2.2. 1,3-Di(4-pentenyl)imidazolium bromide (**2**)

Compound **2** was synthesized as described for **1** from 544 mg (8.0 mmol) of imidazole, 680 mg (8.1 mmol) of sodium hydrogencarbonate, and 2.0 mL (18.7 mmol) of 5-bromopentene in acetonitrile (15 mL). Compound **2** was obtained as a brown oil. Yield: 1.64 g (72%).

Elemental Anal. Calc. for $\text{C}_{13}\text{H}_{21}\text{N}_2\text{Br}$: C, 54.74; H, 7.42; N, 9.82. Found: C, 54.22; H, 7.64; N, 9.99%. ^1H NMR (400.1 MHz, CDCl_3): δ = 10.71 (m, 1H, NCHN),

7.38 (d, $^2J_{\text{HH}} = 2.0$ Hz, 2H, NCHCHN), 5.75 (ddt, $^3J_{\text{HH,trans}} = 17.2$ Hz, $^3J_{\text{HH,cis}} = 10.4$ Hz, $^3J_{\text{HH}} = 6.8$ Hz, 2H, NCH₂CH₂CH₂CH=CH₂), 5.05 (dd, $^2J_{\text{HH}} = 1.2$ Hz, $^3J_{\text{HH}} = 17.2$ Hz, 2H, NCH₂CH₂CH₂CH=CH₂), 5.02 (dd, $^2J_{\text{HH}} = 1.2$ Hz, $^3J_{\text{HH}} = 10.4$ Hz, 2H, NCH₂CH₂CH₂CH=CH₂), 4.37 (t, $^3J_{\text{HH}} = 6.8$ Hz, 4H, NCH₂CH₂CH₂CH=CH₂), 2.15 (dt, $2 \times ^3J_{\text{HH}} = 6.8$ Hz, 4H, NCH₂CH₂CH₂CH=CH₂), 2.05 (tt, $2 \times ^3J_{\text{HH}} = 6.8$ Hz, 4H, NCH₂CH₂CH₂CH=CH₂). ¹³C NMR (50.3 MHz, CDCl₃): $\delta = 135.60$ (NCHN), 135.12 (NCH₂CH₂CH₂CH=CH₂), 121.72 (NCHCHN), 115.42 (NCH₂CH₂CH₂CH=CH₂), 48.33 (NCH₂CH₂CH₂CH=CH₂), 29.19 (NCH₂CH₂CH₂CH=CH₂), 28.31 (NCH₂CH₂CH₂CH=CH₂).

3.3. Palladium complexes

3.3.1. *trans*-Bis[1,3-di(3-butenyl)-imidazolin-2-ylidene]palladium dibromide (**3**)

Samples of 248 mg (0.96 mmol) of **1** and 108 mg (0.48 mmol) of Pd(OAc)₂ were dissolved in THF (15 mL). The reaction mixture was stirred for 12 h at 45 °C. The resulting yellow suspension was then filtered in air. After removal of the solvent complex **3** was obtained as a yellow, air-stable solid. Yield: 226 mg (76%).

Elemental Anal. Calc. for C₂₂H₃₂N₄Br₂Pd: C, 42.70; H, 5.21; N, 9.05. Found: C, 42.25; H, 5.08; N, 9.11%. ¹H NMR (300.1 MHz, THF-*d*₈): $\delta = 6.98$ (s, 4H, NCHCHN), 5.91 (ddt, $^3J_{\text{HH,trans}} = 17.2$ Hz, $^3J_{\text{HH,cis}} = 10.3$ Hz, $^3J_{\text{HH}} = 6.9$ Hz, 4H, NCH₂CH₂CH=CH₂), 5.16 (dd, $^2J_{\text{HH}} = 1.4$ Hz, $^3J_{\text{HH}} = 17.2$ Hz, 4H, NCH₂CH₂CH=CH₂), 5.02 (dd, $^2J_{\text{HH}} = 1.2$ Hz, $^3J_{\text{HH}} = 10.3$ Hz, 4H, NCH₂CH₂CH=CH₂), 4.52 (t, $^3J_{\text{HH}} = 7.4$ Hz, 8H, NCH₂CH₂CH=CH₂), 2.89 (dt, $^3J_{\text{HH}} = 6.9$ Hz, $^3J_{\text{HH}} = 7.4$ Hz, 8H, NCH₂CH₂CH=CH₂). ¹³C NMR (75.4 MHz, THF-*d*₈): $\delta = 171.8$ (NCN), 134.4 (NCH₂CH₂CH=CH₂), 121.9 (NCHCHN), 117.8 (NCH₂CH₂CH=CH₂), 51.1 (NCH₂CH₂CH=CH₂), 36.0 (NCH₂CH₂CH=CH₂). MS (MALDI-TOF) *m/e*: 539 [M–Br]⁺.

3.3.2. *trans*-Bis[1,3-di(4-pentenyl)-imidazolin-2-ylidene]palladium dibromide (**4**)

Complex **4** was synthesized as described for complex **3** from 291 mg (1.02 mmol) of **2** and 115 mg (0.51 mmol) of Pd(OAc)₂ in THF (15 mL). Crystals suitable for the X-ray diffraction study were grown by vapor diffusion of *n*-hexane into a concentrated dichloromethane solution. Yield: 222 mg (64%).

Elemental Anal. Calc. for C₂₆H₄₀N₄Br₂Pd: C, 46.27; H, 5.97; N, 8.30. Found: C, 45.39; H, 5.78; N, 8.19%. ¹H NMR (200.1 MHz, CDCl₃): $\delta = 7.81$ (s, 4H, NCHCHN), 5.83 (m, 4H, NCH₂CH₂CH₂CH=CH₂), 5.06 (m, 4H, NCH₂CH₂CH₂CH=CH₂), 4.99 (m, 4H, NCH₂CH₂CH₂CH=CH₂), 4.26 (t, $^3J_{\text{HH}} = 6.4$ Hz, 8H, NCH₂CH₂CH₂CH=CH₂), 2.16 (m, 16H, NCH₂CH₂CH₂CH=CH₂). ¹³C NMR (50.3 MHz, CDCl₃): $\delta = 168.5$ (NCN), 137.1 (NCH₂CH₂CH₂CH=CH₂), 120.6 (NCHCHN), 115.3 (NCH₂CH₂CH₂CH=CH₂), 50.0 (NCH₂CH₂CH₂CH=CH₂).

=CH₂), 30.5 (NCH₂CH₂CH₂CH=CH₂), 29.5 (NCH₂CH₂CH₂CH=CH₂). MS (MALDI-TOF) *m/e*: 595 [M–Br]⁺, 513 [M–2Br]²⁺.

3.3.3. *cis*-Bis[1,3-diallylimidazolin-2-ylidene]palladium diiodide (**5**)

A mixture of 115 mg (0.51 mmol) of 1,3-diallylimidazolium bromide and 56 mg (0.25 mmol) of Pd(OAc)₂ in THF (10 mL) was treated with 80 mg (0.53 mmol) of sodium iodide. The red suspension was heated under reflux for 12 h. After filtration and removal of the solvent a reddish solid was obtained. This solid was recrystallized from dichloromethane/diethyl ether. Crystals suitable for an X-ray diffraction study were grown by slow diffusion of diethyl ether into a concentrated solution of the complex in dichloromethane. Yield: 36 mg (22%).

Elemental Anal. Calc. for C₁₈H₂₄N₄I₂Pd: C, 32.92; H, 3.68; N, 8.53. Found: C, 32.68; H, 3.62; N, 8.04%. ¹H NMR (400.1 MHz, CDCl₃): $\delta = 6.89$ (s, 4H, NCHCHN), 6.19 (ddt, $^3J_{\text{HH,trans}} = 17.1$ Hz, $^3J_{\text{HH,cis}} = 10.2$ Hz, $^3J_{\text{HH}} = 6.3$ Hz, 4H, NCH₂CH=CH₂), 5.37 (dq, $^3J_{\text{HH}} = 17.1$ Hz, $^4J_{\text{HH}} = 1.3$ Hz, 4H, NCH₂CH=CH₂), 5.31 (dq, $^3J_{\text{HH}} = 10.2$ Hz, $^4J_{\text{HH}} = 1.4$ Hz, 4H, NCH₂CH=CH₂), 5.00 (dt, $^3J_{\text{HH}} = 6.4$ Hz, $^4J_{\text{HH}} = 1.4$ Hz, 8H, NCH₂CH=CH₂). ¹³C NMR (75.4 MHz, CDCl₃): $\delta = 167.5$ (NCN), 132.8 (NCH₂CH=CH₂), 121.0 (NCHCHN), 119.4 (NCH₂CH=CH₂), 53.8 (NCH₂CH=CH₂). MS (MALDI-TOF) *m/e*: 529 [M–I]⁺.

3.4. Nickel complexes

3.4.1. *trans*-Bis[1,3-diallylimidazolin-2-ylidene]nickel diiodide (**6**)

To a mixture of 71 mg (0.15 mmol) of [Ni(CH₃CN)₆](BF₄)₂ and 61 mg (0.3 mmol) of 1,3-diallylimidazolium bromide in dichloromethane (5 mL) were added 44 mg (0.4 mmol) of potassium-*tert*-butoxide and 45 mg (0.3 mmol) of sodium iodide. The mixture was stirred at ambient temperature over night and filtered over silica gel. A red oily solid was obtained which was recrystallized by vapor diffusion of diethyl ether into a concentrated dichloromethane solution. Yield: 39 mg (43%).

¹H NMR (400.1 MHz, CDCl₃): $\delta = 6.79$ (s, 4H, NCHCHN), 6.29 (ddt, $^3J_{\text{HH,trans}} = 17.0$ Hz, $^3J_{\text{HH,cis}} = 10.2$ Hz, $^3J_{\text{HH}} = 6.0$ Hz, 4H, NCH₂CH=CH₂), 5.46 (m, 4H, NCH₂CH=CH₂), 5.45 (m, 8H, NCH₂CH=CH₂), 5.37 (d, $^3J_{\text{HH}} = 10.2$ Hz, 4H, NCH₂CH=CH₂). ¹³C NMR (100.6 MHz, CDCl₃): $\delta = 173.7$ (NCN), 132.8 (NCH₂CH=CH₂), 121.4 (NCHCHN), 119.6 (NCH₂CH=CH₂), 53.6 (NCH₂CH=CH₂). MS (MALDI-TOF) *m/e*: 481 [M–I]⁺, 354 [M–2I]²⁺.

3.4.2. *trans*-Bis[1-methyl-3-allyl-imidazolin-2-ylidene]nickel diiodide (**7**)

Complex **7** was prepared as described for **6** from 71 mg (0.15 mmol) of [Ni(CH₃CN)₆](BF₄)₂ and 61 mg (0.3 mmol) of 1-methyl-3-allylimidazolium bromide, 44 mg (0.4 mmol)

of potassium-*tert*-butoxide and 45 mg (0.3 mmol) sodium iodide in dichloromethane (5 mL). Crystals of **7** were grown by vapor diffusion of diethyl ether into a concentrated dichloromethane solution of **7**. Yield: 32 mg (38%). A mixture of *syn* and *anti* conformers was obtained.

¹H NMR (400.1 MHz, CDCl₃): δ = 6.77, 6.76 (s, 4H, NCHCHN and NCHCHN both conformers), 6.30 (m, 2H, NCH₂CH=CH₂ both conformers), 5.51–5.36 (m, 4H, NCH₂CH=CH₂ both conformers), 5.44 (m, 4H, NCH₂CH=CH₂ both conformers), 4.27, 4.26 (s, 6H, NCH₃ for two conformers). ¹³C NMR (100.6 MHz, CDCl₃): δ = 173.9 (NCN, both conformers), 132.9 (NCH₂CH=CH₂ both conformers), 123.4, 123.3 (NCHCHN for two conformers) 121.1, 121.0 (NCHCHN for two conformers), 119.6, 119.5 (NCH₂CH=CH₂ for two conformers), 53.5 (NCH₂CH=CH₂ for both conformers), 37.9 (NCH₃ for both conformers). MS (MALDI-TOF) *m/e*: 429 [M–I]⁺, 302 [M–2I]⁺.

3.4.3. η⁵-Cyclopentadienyl-[1-methyl-3-allyl-imidazolin-2-ylidene]nickel bromide (**8**)

A mixture of 110 mg (0.54 mmol) of 1-methyl-3-allylimidazolium bromide and 94 mg (0.5 mmol) of nickelocene in THF (10 mL) was heated under reflux for 3 h. During this time the color of the solution changed from green to red. After removal of the solvent unreacted nickelocene was removed by sublimation. The residue was taken up with toluene (20 mL) and was heated to 90 °C for 1 h. Subsequent filtration and removal of the solvent gave **8** as a red solid. Yield: 31 mg (18%).

Elemental Anal. Calc. for C₁₂H₁₅N₂BrNi: C, 44.23; H, 4.64; N, 8.59. Found: C, 43.40; H, 4.46; N, 8.06%. ¹H NMR (400.1 MHz, CD₂Cl₂): δ = 6.99 (d, ²J_{HH} = 1.9 Hz, 1H, NCHCHN), 6.69 (d, ²J_{HH} = 1.9 Hz, 1H, NCHCHN), 6.11 (ddt, ³J_{HH,trans} = 17.1 Hz, ³J_{HH,cis} = 10.4 Hz, ³J_{HH} = 5.6 Hz, 1H, NCH₂CH=CH₂), 5.61 (dd, ²J_{HH} = –15.6 Hz, ³J_{HH} = 5.6 Hz, 1H, NCHHCH=CH₂), 5.32 (m, 1H, NCHHCH=CH₂), 5.30 (m, 1H, NCH₂CH=CHH_{cis}), 5.25 (s, 5H, C₅H₅), 5.18 (dd, ³J_{HH} = 17.1 Hz, ²J_{HH} = 1.2 Hz, 1H, NCH₂CH=CHH_{trans}), 4.25 (s, 3H, NCH₃). ¹³C NMR (100.6 MHz, CDCl₃): δ = 162.4 (NCN), 134.2 (NCH₂CH=CH₂), 124.2 (NCHCHN), 122.4 (NCHCHN), 118.4 (NCH₂CH=CH₂), 91.8 (C₅H₅), 54.8 (NCH₂CH=CH₂), 39.3 (NCH₃). MS (MALDI-TOF) *m/e*: 326 [M]⁺, 245 [M–Br]⁺.

3.4.4. η⁵-Cyclopentadienyl-[1,3-diallylimidazolin-2-ylidene]nickel bromide (**9**)

A mixture of 124 mg (0.54 mmol) of 1,3-diallylimidazolium bromide and 94 mg (0.5 mmol) of nickelocene in THF (10 mL) was stirred at ambient temperature for 3 d. The color of the solution changed from green to red. After removal of the solvent unreacted nickelocene was removed by sublimation. The residue was taken up with toluene (20 mL) and heated to 90 °C for 1 h. Subsequent filtration and removal of the solvent gave **9** as a red solid. Yield: 90 mg (51%).

Elemental Anal. Calc. for C₁₄H₁₇N₂BrNi: C, 44.78; H, 4.86; N, 7.96. No satisfactory microanalytical data could be obtained. However, subsequent reactions with **9** to give **11** confirmed that **9** was indeed obtained. ¹H NMR (400.1 MHz, CD₂Cl₂): δ = 7.01 (s, 2H, NCHCHN), 6.17 (m, ³J_{HH,trans} = 17.1 Hz, ³J_{HH,cis} = 10.4 Hz, ³J_{HH} = 5.5 Hz, 2H, NCH₂CH=CH₂), 5.69 (dd, ²J_{HH} = –15.4 Hz, ³J_{HH} = 5.5 Hz, 2H, NCHHCH=CH₂), 5.37 (m, 2H, NCH₂CH=CHH_{cis}), 5.33 (m, 2H, NCHHCH=CH₂), 5.29 (s, 5H, C₅H₅), 5.23 (m, 2H, NCH₂CH=CHH_{trans}). ¹³C NMR (100.6 MHz, CDCl₃): δ = 160.3 (NCN), 132.1 (NCH₂CH=CH₂), 121.2 (NCHCHN), 116.7 (NCH₂CH=CH₂), 89.8 (C₅H₅), 53.0 (NCH₂CH=CH₂). MS (MALDI-TOF) *m/e*: 352 [M]⁺, 271 [M–Br]⁺.

3.4.5. η⁵-Cyclopentadienyl-[1-methyl-3-allyl-imidazolin-2-ylidene]nickel tetrafluoroborate (**10**)

To a solution of 45 mg (0.14 mmol) of complex **8** in dichloromethane (5 mL) were added 40 mg (0.20 mmol) of silver tetrafluoroborate. The suspension was stirred in the dark over night and subsequently filtered. The solvent was evaporated under reduced pressure and complex **10** was obtained as a brown solid which could be recrystallized by vapor diffusion of diethyl ether into a concentrated dichloromethane solution of the complex. Yield: 23 mg (49%).

¹H NMR (400.1 MHz, CD₂Cl₂): δ = 7.16 (d, ²J_{HH} = 2.0 Hz, 1H, NCHCHN), 6.95 (d, ²J_{HH} = 2.0 Hz, 1H, NCHCHN), 5.85 (dddd, ³J_{HH,trans} = 13.9 Hz, ³J_{HH,cis} = 8.1 Hz, ³J_{HH} = 5.5 Hz, ³J_{HH} = 1.6 Hz, 1H, NCH₂CH=CH₂), 5.79 (s, 5H, C₅H₅), 4.53 (dd, ²J_{HH} = –13.8 Hz, ³J_{HH} = 1.6 Hz, 1H, NCHHCH=CH₂), 4.13 (dd, ²J_{HH} = 1.3 Hz, ³J_{HH} = 8.1 Hz, 1H, NCH₂CH=CHH_{cis}), 4.09 (dd, ²J_{HH} = –13.8 Hz, ³J_{HH} = 1.6 Hz, 1H, NCHHCH=CH₂), 3.63 (s, 3H, NCH₃), 3.22 (dd, ²J_{HH} = 1.3 Hz, ³J_{HH} = 13.9 Hz, 1H, NCHCH=CHH_{trans}). ¹³C NMR (100.6 MHz, CDCl₃): δ = 160.9 (NCN), 126.4 (NCHCHN), 121.6 (NCHCHN), 95.2 (C₅H₅), 78.6 (NCH₂CH=CH₂), 55.2 (NCH₂CH=CH₂), 50.8 (NCH₂CH=CH₂), 38.3 (NCH₃). MS (MALDI-TOF) *m/e*: 245 [M–BF₄]⁺.

3.4.6. η⁵-Cyclopentadienyl-[1,3-diallylimidazolin-2-ylidene]nickel tetrafluoroborate (**11**)

Complex **11** was prepared from 40 mg (0.11 mmol) of complex **9** in dichloromethane (5 mL) and 30 mg (0.15 mmol) of silver tetrafluoroborate as described for **10**. Yield: 21 mg (53%).

¹H NMR (400.1 MHz, CD₂Cl₂): δ = 7.24 (d, ²J_{HH} = 1.9 Hz, 1H, NCHCHN), 6.94 (d, ²J_{HH} = 1.9 Hz, 1H, NCHCHN), 6.00 (ddt, ³J_{HH,trans} = 17.1 Hz, ³J_{HH,cis} = 10.6 Hz, ³J_{HH} = 5.0 Hz, 1H, NCH₂CH=CH₂, not coordinated), 5.89 (dddd, ³J_{HH,trans} = 13.9 Hz, ³J_{HH,cis} = 8.2 Hz, ³J_{HH} = 5.5 Hz, ³J_{HH} = 1.5 Hz, 1H, NCH₂CH=CH₂, coordinated), 5.76 (s, 5H, C₅H₅), 5.39 (m, 1H, NCH₂CH=CHH_{cis}, not coordinated), 5.05 (m, 1H, NCH₂CH=CHH_{trans}, not coordinated), 4.62 (dd, ²J_{HH} = –14.2 Hz, ³J_{HH} = 5.5 Hz, 1H, NCHHCH=CH₂, coordinated), 4.51

Table 1
Crystallographic and data collection details for **4–7** and **10–11**

Compound	4	5	6	7	10	11
Formula	C ₂₆ H ₄₀ Br ₂ Br ₂ Pd	C ₁₈ H ₂₄ N ₄ I ₂ Pd	C ₁₈ H ₂₄ N ₄ I ₂ Ni	C ₁₄ H ₂₀ N ₄ I ₂ Ni	C ₁₂ H ₁₅ N ₂ BF ₄ Ni	C ₁₄ H ₁₇ N ₂ BF ₄ Ni
Molecular weight	674.84	656.61	608.92	556.85	332.78	358.82
Crystal size (mm)	0.42 × 0.32 × 0.30	0.34 × 0.10 × 0.07	0.21 × 0.15 × 0.02	0.21 × 0.06 × 0.05	0.20 × 0.07 × 0.04	0.41 × 0.09 × 0.03
Space group	<i>P2₁/c</i>	<i>P2₁/n</i>	<i>P2₁/c</i>	<i>P2₁/n</i>	<i>P2₁/c</i>	<i>P2₁/c</i>
<i>a</i> (Å)	14.316(2)	11.426(2)	8.3702(15)	8.8112(13)	8.4296(12)	7.138(2)
<i>b</i> (Å)	16.431(3)	15.469(3)	18.290(3)	8.9693(13)	7.5922(11)	16.442(4)
<i>c</i> (Å)	14.145(2)	12.833(2)	8.1742(15)	12.135(2)	21.314(3)	12.694(3)
β (°)	119.318(3)	90.599(3)	117.423(3)	103.260(3)	100.654(3)	93.227(5)
<i>V</i> (Å ³)	2901.2(8)	2268.1(6)	1110.8(3)	933.5(2)	1340.5(3)	1487.4(6)
<i>Z</i>	4	4	2	2	4	4
<i>D</i> _{calc} (g cm ⁻³)	1.545	1.923	1.821	1.981	1.649	1.602
μ (mm ⁻¹)	3.414	3.548	3.661	4.345	1.483	1.343
θ -Range (°)	2.05–30.01	2.06–27.50	2.23–27.50	2.60–24.99	1.94–25.00	2.03–30.07
Unique reflections	8449	5196	2549	1640	2342	4319
<i>R</i> [<i>I</i> > 2 σ (<i>I</i>)]	<i>R</i> ₁ = 0.0450 <i>wR</i> ₂ = 0.0817	<i>R</i> ₁ = 0.0303 <i>wR</i> ₂ = 0.0652	<i>R</i> ₁ = 0.0354 <i>wR</i> ₂ = 0.0708	<i>R</i> ₁ = 0.0413 <i>wR</i> ₂ = 0.0955	<i>R</i> ₁ = 0.0463 <i>wR</i> ₂ = 0.0957	<i>R</i> ₁ = 0.0416 <i>wR</i> ₂ = 0.0901
Goodness-of-fit	1.042	1.046	1.102	1.070	1.206	1.023
Peak/hole	0.893/–0.830	1.303/–0.392	0.913/–0.542	1.757/–0.666	0.458/–0.350	0.388/–0.363

(m, 1H, NCHHCH=CH₂, not coordinated), 4.49 (m, 1H, NCHHCH=CH₂, not coordinated), 4.15 (m, H, NCHHCH=CH₂, coordinated and 1H, NCH₂CH=CHH_{cis}, coordinated), 3.26 (dd, ²*J*_{HH} = 0.8 Hz, ³*J*_{HH} = 14.0 Hz, 1H, NCH₂CH=CHH_{trans}, coordinated). ¹³C NMR (100.6 MHz, CDCl₃): δ = 161.3 (NCN), 132.4 (NCH₂CH=CH₂, not coordinated), 125.2 (NCHCHN), 122.2 (NCHCHN), 119.1 (NCH₂CH=CH₂, not coordinated), 95.5 (C₅H₅), 78.7 (NCH₂CH=CH₂, coordinated), 55.5 (NCH₂CH=CH₂, coordinated), 53.3 (NCH₂CH=CH₂, not coordinated), 51.2 (NCH₂CH=CH₂, coordinated). MS (MALDI-TOF) *m/e*: 271 [M–BF₄]⁺.

3.5. Structure determinations

Diffraction data for complexes **4–7**, **10**, and **11** were collected with a Bruker AXS APEX CCD diffractometer equipped with a rotating anode at 153(2) K using graphite-monochromated Mo K α radiation. Data were collected over the full sphere and were corrected for absorption. Structure solutions were found by the Patterson method. Structure refinement was carried out by full-matrix least squares on $|F|^2$ with SHELXL-97 [22] using first isotropic and later anisotropic displacement parameters for all non-hydrogen atoms. Additional data collection and refinement parameters are summarized in Table 1.

4. Supplementary material

CCDC 641957, 641958, 641959, 641960, 641961 and 641962 contain the supplementary crystallographic data for **4**, **5**, **6**, **7**, **10** and **11**. These data can be obtained free of charge via <http://www.ccdc.cam.ac.uk/conts/retrieving.html>, or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: (+44) 1223-336-033; or e-mail: deposit@ccdc.cam.ac.uk.

Acknowledgments

This work has been supported by the Deutsche Forschungsgemeinschaft (SFB 424) and the Fonds der Chemischen Industrie.

References

- [1] (a) W.A. Herrmann, C. Köcher, *Angew. Chem., Int. Ed.* 36 (1997) 2162;
(b) T. Weskamp, V.P.W. Böhm, W.A. Herrmann, *J. Organomet. Chem.* 600 (2000) 12;
(c) D. Bourissou, O. Guerret, F.P. Gabbaï, G. Bertrand, *Chem. Rev.* 100 (2000) 39;
(d) W.A. Herrmann, *Angew. Chem., Int. Ed.* 41 (2002) 1290;
(e) R.H. Crabtree, *Pure Appl. Chem.* 75 (2003) 435;
(f) K.J. Cavell, D.S. McGuinness, *Coord. Chem. Rev.* 248 (2004) 671;
(g) V. César, S. Bellemin-Laponnaz, L.H. Gade, *Chem. Soc. Rev.* 33 (2004) 619;
(h) N.M. Scott, S.P. Nolan, *Eur. J. Inorg. Chem.* (2005) 1815;
(i) F.E. Hahn, *Angew. Chem., Int. Ed.* 45 (2006) 1348.
- [2] (a) J.E. Hill, T.A. Nile, *J. Organomet. Chem.* 137 (1977) 293;
(b) M.F. Lappert, R.K. Maskell, *J. Organomet. Chem.* 264 (1984) 217;
(c) M.G. Gardiner, W.A. Herrmann, C.-P. Reisinger, J. Schwarz, M. Spiegler, *J. Organomet. Chem.* 572 (1999) 239;
(d) A.C. Hillier, H.M. Lee, E.D. Stevens, S.P. Nolan, *Organometallics* 20 (2001) 4246;
(e) S. Lee, N.A. Beare, J.F. Hartwig, *J. Am. Chem. Soc.* 123 (2001) 8410;
(f) G.A. Grasa, M.S. Viciu, J. Huang, C. Zhang, M.L. Trudell, S.P. Nolan, *Organometallics* 21 (2002) 2866;
(g) M. Muehlhofer, T. Strassner, W.A. Herrmann, *Angew. Chem., Int. Ed.* 41 (2002) 1745.
- [3] (a) D.S. Mc Guinness, K.J. Cavell, *Organometallics* 19 (2000) 741;
(b) J.C.C. Chen, I.J.B. Lin, *Organometallics* 19 (2000) 5113;
(c) D.S. McGuinness, W. Mueller, P. Wasserscheid, K.J. Cavell, D.W. Skelton, A.H. White, U. Englert, *Organometallics* 21 (2002) 175;
(d) D. Zhang, G.-X. Jin, *Organometallics* 22 (2003) 2851;
(e) D. Zhang, G.-X. Jin, L.H. Weng, F. Wang, *Organometallics* 23 (2004) 3270;

- (f) D. Kremzow, G. Seidel, C.W. Lehmann, A. Fürstner, *Chem. Eur. J.* 11 (2005) 1833.
- [4] (a) I.P. Beletskaya, A.V. Cheprakov, *Chem. Rev.* 100 (2000) 3009;
(b) R.B. Bedford, *Chem. Commun.* (2003) 1787;
(c) R.B. Bedford, C.S.J. Cazin, D. Holder, *Coord. Chem. Rev.* 248 (2004) 2283;
(d) E. Peris, R.H. Crabtree, *Coord. Chem. Rev.* 248 (2004) 2239;
(e) J. Dupont, R.F. de Souza, P.A.Z. Suarez, *Chem. Rev.* 102 (2002) 3667;
(f) N.J. Whitcombe, K.K. Hii, S.E. Gibson, *Tetrahedron* 57 (2001) 7449;
(g) A.C. Hillier, G.A. Grasa, M.S. Viciu, H.M. Lee, C. Yang, S.P. Nolan, *J. Organomet. Chem.* 653 (2002) 69.
- [5] (a) E. Drent, P. Arnoldy, P.H.M. Budzelaar, *J. Organomet. Chem.* 475 (1994) 57;
(b) W. Keim, *Angew. Chem., Int. Ed. Engl.* 29 (1990) 235.
- [6] (a) W.A. Herrmann, C. Köcher, L.J. Gooßen, G.R.J. Artus, *Chem. Eur. J.* 2 (1996) 1627;
(b) W.A. Herrmann, L.J. Gooßen, M. Spiegler, *J. Organomet. Chem.* 547 (1997) 357;
(c) X. Wang, S. Liu, G.-X. Jin, *Organometallics* 23 (2004) 6002;
(d) H.V. Huynh, C.H. Yeo, G.K. Tan, *Chem. Commun.* (2006) 3833.
- [7] C.-Y. Liu, D.-Y. Chen, G.-H. Lee, S.-M. Peng, S.-T. Liu, *Organometallics* 15 (1996) 1055.
- [8] (a) F.E. Hahn, C. Holtgrewe, T. Pape, M. Martin, E. Sola, L.A. Oro, *Organometallics* 24 (2005) 2203;
(b) F.E. Hahn, B. Heidrich, T. Pape, A. Hepp, M. Martin, E. Sola, L.A. Oro, *Inorg. Chim. Acta* 359 (2006) 4840.
- [9] (a) H.V. Huynh, N. Meier, T. Pape, F.E. Hahn, *Organometallics* 25 (2006) 3012;
(b) F.E. Hahn, N. Meier, T. Pape, *Z. Naturforsch., Teil B* 61b (2006) 820.
- [10] (a) H. Lemkuhl, J. Näser, G. Mehler, T. Keil, F. Danowski, R. Benn, R. Mynott, G. Schroth, B. Gabor, C. Krüger, P. Betz, *Chem. Ber.* 124 (1991) 441;
(b) D. Gareau, C. Sui-Seng, L.F. Groux, F. Brisse, D. Zargarian, *Organometallics* 24 (2005) 4003.
- [11] C. Holtgrewe, C. Diedrich, T. Pape, S. Grimme, F.E. Hahn, *Eur. J. Org. Chem.* (2006) 3116.
- [12] (a) F.E. Hahn, B. Heidrich, T. Lügger, T. Pape, *Z. Naturforsch., Teil B* 59b (2004) 1519;
(b) F.E. Hahn, C. Holtgrewe, T. Pape, *Z. Naturforsch., Teil B* 59b (2004) 1051;
(c) H.V. Huynh, C. Holtgrewe, T. Pape, L.L. Koh, F.E. Hahn, *Organometallics* 25 (2006) 245.
- [13] (a) B. Cetinkaya, E. Centinkaya, M.F. Lappert, *J. Chem. Soc., Dalton Trans.* (1973) 906;
(b) H.V. Huynh, J.H.H. Ho, T.C. Neo, L.L. Koh, *J. Organomet. Chem.* 690 (2005) 3854;
(c) H.V. Huynh, T.C. Neo, G.K. Tan, *Organometallics* 25 (2006) 1298.
- [14] W.A. Herrmann, G. Gerstberger, M. Spiegler, *Organometallics* 16 (1997) 2209.
- [15] W.A. Herrmann, M. Elison, J. Fischer, C. Köcher, G.R.J. Artus, *Angew. Chem., Int. Ed. Engl.* 34 (1995) 2371.
- [16] H. Glas, E. Herdtweck, M. Spiegler, A.-K. Pleier, W.R. Thiel, *J. Organomet. Chem.* 626 (2001) 100.
- [17] (a) D. Enders, H. Gielen, G. Raabe, J. Runsink, J.H. Teles, *Chem. Ber.* 129 (1996) 1483;
(b) A.R. Chianese, X. Li, M.C. Janzen, J.W. Faller, R.H. Crabtree, *Organometallics* 22 (2003) 1663;
(c) T. Weskamp, W.C. Schattenmann, M. Spiegler, W.A. Herrmann, *Angew. Chem., Int. Ed.* 37 (1998) 2490;
(d) I. Özdemir, B. Yigit, B. Cetinkaya, D. Ülkü, M.N. Tahir, C. Arici, *J. Organomet. Chem.* 633 (2001) 27;
(e) M.J. Doyle, M.F. Lappert, *J. Chem. Soc., Chem. Commun.* (1974) 679;
(f) D. Enders, H. Gielen, *J. Organomet. Chem.* 617–618 (2001) 70.
- [18] D.S. Clyne, J. Jin, E. Genest, J.C. Gallucci, T.V. RajanBabu, *Org. Lett.* 2 (2000) 1125.
- [19] C.D. Abernethy, A.H. Cowley, R.A. Jones, *J. Organomet. Chem.* 596 (2000) 3.
- [20] M. Tamm, F.E. Hahn, *Inorg. Chim. Acta* 288 (1999) 47.
- [21] R.A. Kelly III, N.M. Scott, S. Díez-González, E.D. Stevens, S.P. Nolan, *Organometallics* 24 (2005) 3442.
- [22] G.M. Sheldrick, *SHELXL-97*, Universität Göttingen, Germany, 1997.